Kyverna Therapeutics
KYTX
111 hedge funds and large institutions have $301M invested in Kyverna Therapeutics in 2026 Q1 according to their latest regulatory filings, with 27 funds opening new positions, 31 increasing their positions, 35 reducing their positions, and 14 closing their positions.
202% more call options, than puts
Call options by funds: $1.41M | Put options by funds: $468K
93% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 14
12% more funds holding
Funds holding: 99 → 111 (+12)
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
6% less capital invested
Capital invested by funds: $321M → $301M (-$20.2M)
11% less repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 35
20.32% less ownership
Funds ownership: 77.93% → 57.62% (-20%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$4.17M |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$3.92M |
| 3 |
Millennium Management
New York
|
+$3.43M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$2.82M |
| 5 |
BlackRock
New York
|
+$2.77M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$9.72M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
-$5.64M |
| 3 |
RA
RFG Advisory
Birmingham,
Alabama
|
-$4.18M |
| 4 |
HCM
Heights Capital Management
San Francisco,
California
|
-$2.56M |
| 5 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$1.83M |
KYTX Hedge Fund Activity: Q1 2026 in Review
111 of the 8,130 institutional investors tracked by Wall St. Rank reported a position in Kyverna Therapeutics (KYTX) for Q1 2026, worth a combined $301M — down 6.3% from $321M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new KYTX positions and 14 closed out — a net gain of 13 holders — while 31 added to existing stakes and 35 trimmed.
The largest buyer was AIGH Capital Management, adding an estimated $4.17M. The largest seller was Adage Capital Partners, cutting an estimated $9.72M.
- 111 institutional investors held Kyverna Therapeutics (KYTX) as of Q1 2026, up from 99 in Q4 2025.
- Funds reported $301M of Kyverna Therapeutics stock for Q1 2026, down 6.3% quarter-over-quarter.
- 27 funds opened new Kyverna Therapeutics positions in Q1 2026 and 14 closed out, a net change of +13 holders.
- The largest Kyverna Therapeutics buyer in Q1 2026 was AIGH Capital Management, an estimated $4.17M added.
- The largest Kyverna Therapeutics seller in Q1 2026 was Adage Capital Partners, an estimated $9.72M sold.
Based on aggregated 13F filings for Q1 2026.